Table 1. Patient and tumor characteristics.
| Characteristic | CEA-positive | CYFRA 21-1-positive | |||||
|---|---|---|---|---|---|---|---|
| Decreasing group, n (%) | Non-decreasing group, n (%) | P value | Decreasing group, n (%) | Non-decreasing group, n (%) | P value | ||
| Total | 79 (82.3) | 17 (17.7) | 39 (70.9) | 16 (29.1) | |||
| Age, years | 0.425 | 1 | |||||
| <70 | 41 (51.9) | 11 (64.7) | 25 (64.1) | 10 (62.5) | |||
| ≥70 | 38 (48.1) | 6 (35.3) | 14 (35.9) | 6 (37.5) | |||
| Sex | 0.002 | 0.146 | |||||
| Male | 51 (64.6) | 17 (100.0) | 29 (74.4) | 15 (93.8) | |||
| Female | 28 (35.4) | 0 (0.0) | 10 (25.6) | 1 (6.2) | |||
| History of smoking | 0.005 | 0.026 | |||||
| None | 24 (30.4) | 0 (0.0) | 10 (25.6) | 0 (0.0) | |||
| Current + former | 55 (69.6) | 17 (100.0) | 29 (74.4) | 16 (100.0) | |||
| ECOG PS | 0.133 | 0.501 | |||||
| 0, 1 | 69 (87.3) | 12 (70.6) | 38 (97.4) | 15 (93.8) | |||
| 2 | 10 (12.7) | 5 (29.4) | 1 (2.6) | 1 (6.2) | |||
| Stage | 0.405 | 0.453 | |||||
| IIIB | 8 (10.1) | 3 (17.6) | 6 (15.4) | 4 (25.0) | |||
| IV + postoperative recurrence | 71 (89.9) | 14 (82.4) | 33 (84.6) | 12 (75.0) | |||
| Histology | 0.082 | 0.565 | |||||
| Adenocarcinoma | 12 (15.2) | 6 (35.3) | 23 (59.0) | 8 (50.0) | |||
| Non-adenocarcinoma | 67 (84.8) | 11 (64.7) | 16 (41.0) | 8 (50.0) | |||
| EGFR mutation status | 0.098 | 0.089 | |||||
| Positive | 32 (40.5) | 3 (17.6) | 8 (20.5) | 0 (0.0) | |||
| Negative | 47 (59.5) | 14 (82.4) | 31 (79.5) | 16 (100.0) | |||
| Tumor marker levels at baseline | 0.793 | 1 | |||||
| High¶ | 38 (48.1) | 9 (52.9) | 19 (48.7) | 8 (50.0) | |||
| Low | 41 (51.9) | 8 (47.1) | 20 (51.3) | 8 (50.0) | |||
| Imaging-based response | 0.019 | 0.001 | |||||
| PR, SD | 53 (67.1) | 8 ( 47.1) | 23 (59.0) | 3 ( 18.8) | |||
| PD | 16 (20.3) | 9 ( 52.9) | 11 (28.2) | 13 ( 81.2) | |||
| NE | 10 (12.7) | 0 ( 0.0) | 5 (12.8) | 0 ( 0.0) | |||
¶, high tumor marker levels at baseline were defined as >30 mg/dL for CEA and >10 mg/dL for CYFRA. CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin 19 fragment; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; PR, partial response.